Recalibrating the risks and benefits of lithium therapy

Br J Psychiatry. 2017 Jul;211(1):1-2. doi: 10.1192/bjp.bp.116.193789.

Abstract

Recent data might subtly recalibrate the risk/benefit ratio of lithium, the prototypical mood stabiliser for bipolar disorder. There are hints that lithium might be associated with a reduction in dementia risk and as noted in this Journal, a surprising reduction in the risk of cancer.

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antimanic Agents / therapeutic use
  • Bipolar Disorder / drug therapy
  • Dementia / drug therapy*
  • Humans
  • Lithium Compounds / adverse effects
  • Lithium Compounds / therapeutic use*
  • Neoplasms / chemically induced*

Substances

  • Antimanic Agents
  • Lithium Compounds